News
The OIS Index of ophthalmic stocks followed global stock markets into bear market territory in Q1, declining 21.2%, in line with the overall US stock…
Read More
The explosion of healthcare information technology has engendered a chaotic landscape of infinite terabytes of disparate but mutually relevant data segregated in infinite silos where…
Read More
Adverum, a company pioneering novel gene therapies for ocular diseases, believes a gene therapy treatment for wet age-related macular degeneration (AMD) can reduce treatment burden…
Read More
Once again the eye proved to be the pioneer target in a new gene therapy approach, with the use in February of an agent utilizing…
Read More
Last week we heard firsthand at OIS@SECO’s second annual event just what it means to be innovative in the field of optometry. Leading off the…
Read More
Editor’s Note: The FDA just approved Allergan’s Durysta (bimatoprost implant) 10 mcg for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension on…
Read More
As reports of intraocular inflammation and vasculitis have cast caution onto the uptake of the newest approved anti-VEGF drug, Novartis’ Beovu (brolucizumab), the quest to…
Read More
Israel’s second name is “start-up nation,” and there are anywhere from 50-70 companies developing products for the eye care industry in Israel. From a monetary…
Read More
“Innovation remains the largest driver of healthcare cost increase,” said David Parke II, MD, American Academy of Ophthalmology CEO, during the Glaucoma Research Foundation’s (GRF)…
Read More
The use of ranibizumab 0.5 mg for proliferative diabetic retinopathy (PDR) compared with panretinal photocoagulation (PRP) appeared to be more cost effective for patients with…
Read More
Media coverage of AbbVie’s (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in June was both bullish and bearish. In our initial coverage, we took a…
Read More
Globally, the myopia market may be worth upwards of $28 billion by 2026, with single prescription corrective lenses holding a significant market share, according to…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")